ArchiMed buys Clean Cells in SBO from Sodero Gestion

Co-founders Olivier Boisteau and Marc Meichenin retain stakes in the business, while a third co-founder, Frederic Henry, and private investor Valerie Allain-Dupre have divested their stakes.

ArchiMed is currently investing via €310m vehicle Med II and Med Platform I. The former writes equity cheques of €5-50m, while the latter makes investments of €50-300m in platform companies.

Company
Founded in 2000 and based in Boufféré, Clean Cells provides a range of services including tests related to the viral and biological safety of biopharmaceuticals, the production of cell and virus banks, and the production of experimental drugs such as cell therapy products and therapeutic phage.

Its customers include biopharmaceutical companies, contract manufacturing organisations, cell culture product manufacturers, early clinical-stage companies, contract research organisations and academic research laboratories.

Clean Cells is forecasted to generate a turnover of €8m this year.

People
ArchiMed – André-Michel Ballester, Denis Ribon (partners).
Clean Cells – Olivier Boisteau, Marc Meichenin (founders). 

Advisers
Equity – Lamartine Conseil (legal); Mazars (corporate finance).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• Exits
• France
• Healthcare
• France
• Mazars